NCT00875394View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 1, 2007

Primary Completion Date

June 27, 2008

Study Completion Date

June 27, 2008

Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
DRUG

sitagliptin phosphate

sitagliptin 100 mg Once a day (QD) for 24 weeks

DRUG

Comparator: metformin

metformin 850 mg Twice a day (BID) for 24 weeks

DRUG

Comparator: metformin

metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks

DRUG

Comparator: Antidiabetic Standard of Care

Patient can take any oral antidiabetic drug (other than metformin)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00875394 - Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189) | Biotech Hunter | Biotech Hunter